INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) Files An 8-K Other Events

Item8.01.

On February13, 2017, we announced that we had entered into a
License and Collaboration Agreement (the Agreement) with
ApolloBio Corp. (ApolloBio). While the Agreement has been
executed by the parties, the Agreement by its terms will become
effective on the date that the ApolloBio board of directors and
stockholders approve the Agreement, which is anticipated to occur
in the next few weeks, at which time we will file another Form
8-K to report the Agreement as of the effective date.

Under the collaboration and license agreement, we will receive
$15 million in upfront and near term payments comprised of an
initial $3 million signing fee and a $12 million milestone upon
lifting of the VGX-3100 phase 3 pre-initiation clinical hold by
the FDA. Under a separate stock purchase agreement, ApolloBio
will invest in our common stock subsequent to lifting of the
clinical hold at a volume weighted average price encompassing a
trading period prior to and following the lifting of the clinical
hold. The stock purchase agreement will become effective at the
same time the Agreement becomes effective, at which time we will
file another Form 8-K to report the stock purchase agreement as
of the effective date. The aggregate investment under the stock
purchase agreement, which is expected to be completed in the
first half of 2017, will not exceed $35 million and may be a
lower amount such that ApolloBio will not be our largest
shareholder.

ApolloBio will fund all clinical development costs within the
licensed territory, and will pay us up to $20 million based upon
the achievement of certain regulatory milestones in the United
States, China and Korea, and double digit royalties on net sales
of VGX-3100. The agreements are subject to Peoples Republic of
China (PRC) corporate and regulatory approvals, and payments are
subject to PRC currency approvals.

On February13, 2017, we issued a press release, which file as
Exhibit 99.1 to, and incorporate by reference in, this Form 8-K
current report as though fully set forth herein.

About INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO)

Inovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) Recent Trading Information

INOVIO PHARMACEUTICALS, INC. (NASDAQ:INO) closed its last trading session up +0.36 at 6.75 with 444,692 shares trading hands.